Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GTx To File NDA For Acapodene In Early 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III interim analysis finds the selective estrogen receptor modulator lowers cholesterol associated with androgen deprivation therapy for prostate cancer.

You may also be interested in...



GTx Closer To Filing NDA For Acapodene With Promising Phase III Results

Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.

GTx Closer To Filing NDA For Acapodene With Promising Phase III Results

Findings of reduced vertebral fracture risk mean drug could offer 39-month median survival improvement, company tells DAILY.

GTx Phase IIIb Study Will Evaluate Therapy For Prostate Cancer Treatment Side Effects

GTx is initiating an extension of its Phase III clinical trial of Acapodene in prostate cancer patients.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel